An Investigation Into the Mechanisms of Action of a Combined Long Acting Beta Agonist/Inhaled Corticosteroid (Seretide 500 Accuhaler) on the Bacterial Colonisation, Immunology and Inflammation of Patients With Chronic Obstructive Pulmonary Disease (IMAS)

NCT00974805 Phase 4 COMPLETED

This study is investigating the possible mechanisms of action of an inhaled treatment (Seretide), currently used worldwide in millions of patients with COPD (Chronic Obstructive Pulmonary Disease) and how it improves the symptoms of these patients. Previous research has failed to identify the mechanisms at play other than dilation of the airways. The research community has long thought the mechanism to be immune based or anti inflammatory but despite intensive research this has not yet been identified.

Details

Lead sponsor	University of Southampton
Phase	Phase 4
Status	COMPLETED
Enrolment	48
Start date	2010-02
Completion	2012-02

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

• Seretide 500 Accuhaler

Primary outcomes

• The primary outcome measures are change in cell type and activation status — 56 days

Countries

United Kingdom